Three pivotal MDD trial failures for Neumora lead to staffing cuts

The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate Following the Phase III failures, the workforce will be cut by 35%. Credit: Andrii Yalanskyi / Shutterstock.com Neumora Therapeutics is cutting its staff by 35% following Phase III trial failures of its multiple depressive disorder (MDD) candidate. The Phase III KOASTAL-2 and -3 studies of navacaprant for the treatment of MDD did not achieve statistical significance…

Source: Clinical Trials Arena